Freedom Broker downgrades Amgen stock rating on valuation despite raising price target
Freedom Broker downgrades Amgen stock rating on valuation despite raising price target Investing.com
Covered in this story
Analyst targets on Amgen
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.